Evolving trends and drug class dynamics in drug-induced fatty liver disease over two decades

Abstract

Aim: Drug-induced fatty liver disease (DIFLD) is an increasing concern due to both new and existing medications. This study aims to analyze trends in drug associations with DIFLD, identify vulnerable populations, and provide insights for better prevention and management strategies.

Methods: Reports of steatotic liver disease (SLD) and liver failure from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) for the period 2004-2023 were analyzed separately after deduplication per guidelines. Drugs were categorized by therapeutic class, and trends were assessed using linear regression. Subgroup analyses addressed age, sex and regional difference.

Results: Between 2004 and 2023, a total of 15,269 SLD cases were reported in FAERS, with annual cases increasing significantly from 481 in 2004 to 1,413 in 2023 (+46.00 cases/year). Among implicated drug classes, monoclonal antibodies (MAbs), antipsychotics, and disease-modifying antirheumatic drugs were the most frequently reported, with MAbs showing the most rapid increase in reporting rate (+11.77 cases/year). Adalimumab was the leading single drug linked to DIFLD, accounting for 5.81% of all reported cases. Subgroup analyses revealed that adults aged 18-64 years (75.65%) and females (59.12%) were the most affected populations. Notably, hypoglycemic agents showed a pronounced increase in female cases. The United States accounted for 45.44% of cases, with distinct drug-class patterns observed across regions.

Conclusion: This study reveals significant trends in the association between drugs and DIFLD and liver failure, stressing the need for region-specific pharmacovigilance and tailored interventions to mitigate risks and optimize treatment outcomes.

Keywords

FAERS / DIFLD / adverse drug event / steatotic liver disease / liver failure

References

[1] López-Pascual E,Perez-Rojas J.Drug-induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways.Int J Mol Sci2024;25:5203 PMCID:PMC11121209

[2] Kleiner DE, Chalasani NP, Lee WM, et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.Hepatology2014;59:661-70 PMCID:PMC3946736

[3] Ipsen DH,Tveden-Nyborg P.Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.Cell Mol Life Sci2018;75:3313-27 PMCID:PMC6105174

[4] Begriche K,Robin MA,Fromenty B.Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease.Hepatology2013;58:1497-507

[5] Chalasani N, Younossi Z, Lavine JE, et al; American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.Gastroenterology2012;142:1592-609

[6] Kolaric TO,Kuna L.Drug-induced fatty liver disease: pathogenesis and treatment.J Clin Transl Hepatol2021;9:731-7 PMCID:PMC8516847

[7] Hosack T,Biswas S.Drug-induced liver injury: a comprehensive review.Therap Adv Gastroenterol2023;16:17562848231163410 PMCID:PMC10031606

[8] Aithal GP.Hepatotoxicity related to antirheumatic drugs.Nat Rev Rheumatol2011;7:139-50

[9] Hansel TT,Singer T,George AJ.The safety and side effects of monoclonal antibodies.Nat Rev Drug Discov2010;9:325-38

[10] Pfefferlé M,Buzzi RM.Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity.J Immunother Cancer2023;11:e005718 PMCID:PMC9809320

[11] Bath RK,Forouhar FA.A review of methotrexate-associated hepatotoxicity.J Dig Dis2014;15:517-24

[12] Di Pasqua LG, Cagna M, Berardo C, Vairetti M, Ferrigno A. Detailed molecular mechanisms involved in drug-induced non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: an update.Biomedicines2022;10:194 PMCID:PMC8774221

[13] Todorović Vukotić N, Đorđević J, Pejić S, Đorđević N, Pajović SB. Antidepressants- and antipsychotics-induced hepatotoxicity.Arch Toxicol2021;95:767-89 PMCID:PMC7781826

[14] Slim M,Gonzalez-Jimenez A.Hepatic safety of atypical antipsychotics: current evidence and future directions.Drug Saf2016;39:925-43

[15] Carli M,Longoni B.Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences.Pharmaceuticals2021;14:238 PMCID:PMC8001502

[16] Leise MD,Talwalkar JA.Drug-induced liver injury.Mayo Clin Proc2014;89:95-106

[17] Anand K,Trachtenberg B.Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS).JACC CardioOncol2019;1:172-8 PMCID:PMC8352117

[18] Kamimura H,Kimura N.Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019.Hepatol Res2023;53:556-68

[19] Yang Z,Yu M.GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS.Front Pharmacol2022;13:925377 PMCID:PMC9640975

[20] Brown EG,Wood S.The medical dictionary for regulatory activities (MedDRA).Drug Saf1999;20:109-17

[21] Shu Y,Liu Y,Zhang Q.A real-world disproportionality analysis of Olaparib: data mining of the public version of FDA Adverse Event Reporting System.Clin Epidemiol2022;14:789-802 PMCID:PMC9250344

[22] Wang Y,Yang H.A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil.Andrology2024;12:785-92

[23] Cui Z,Wang L.A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?.Front Pharmacol2023;14:1259908 PMCID:PMC10637489

[24] Posner J,Brier T.Monoclonal antibodies: past, present and future. In: Barrett JE, Page CP, Michel MC, editors. Concepts and principles of pharmacology. Cham: Springer International Publishing; 2019. pp. 81-141.

[25] Boyiadzis M.Approved monoclonal antibodies for cancer therapy.Expert Opin Biol Ther2008;8:1151-8

[26] Perosa F,Prete M.Monoclonal antibodies in the immunotherapy of autoimmune diseases.Ann Ital Med Int2001;16:220-32

[27] Chun LJ,Busuttil RW.Acetaminophen hepatotoxicity and acute liver failure.J Clin Gastroenterol2009;43:342-9

[28] De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.JHEP Rep2020;2:100170 PMCID:PMC7648167

[29] Chen J,Liu Y.Kupffer cells in non-alcoholic fatty liver disease: friend or foe?.Int J Biol Sci2020;16:2367-78 PMCID:PMC7378652

[30] Schmidt S,Gaiser C,Suter-Dick L.Methotrexate-induced liver injury is associated with oxidative stress, impaired mitochondrial respiration, and endoplasmic reticulum stress in vitro.Int J Mol Sci2022;23:15116 PMCID:PMC9735468

[31] Di Martino V,Verhoeven F.Busting the myth of methotrexate chronic hepatotoxicity.Nat Rev Rheumatol2023;19:96-110

[32] French JB,Ghabril M,Bonkovsky HL.Hepatotoxicity associated with the use of anti-TNF-α agents.Drug Saf2016;39:199-208 PMCID:PMC4752395

[33] Ramadori G.Effects of systemic chemotherapy on the liver.Ann Hepatol2010;9:133-43

[34] Meunier L.Chemotherapy-associated steatohepatitis.Ann Hepatol2020;19:597-601

[35] Tolman KG.Hepatotoxicity of the thiazolidinediones.Clin Liver Dis2003;7:369-79, vi

[36] Khan RS,Cusi K.Modulation of insulin resistance in nonalcoholic fatty liver disease.Hepatology2019;70:711-24

[37] Wu L,Gao N.Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level.Heliyon2024;10:e32730 PMCID:PMC11226829

[38] Sørensen P,Madsen EL,Poulsen MR.Reversible hepatic steatosis in patients treated with interferon alfa-2A and 5-fluorouracil.Cancer1995;75:2592-6

[39] Choudhari P.Updates in the management of pediatric dyslipidemia.Curr Opin Lipidol2023;34:156-61

[40] Kumar N,Arora MK.Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database.Eur J Clin Pharmacol2024;80:1685-95

[41] Kaplowitz N,Simon FR.Drug-induced hepatotoxicity.Ann Intern Med1986;104:826-39

[42] Kral JG,Pierson RN Jr.Body fat topography as an independent predictor of fatty liver.Metabolism1993;42:548-51

[43] Adams GP.Monoclonal antibody therapy of cancer.Nat Biotechnol2005;23:1147-57

[44] Tran K. Exercise for the treatment of ankle sprain: a review of clinical effectiveness and guidelines. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563007/. [Last accessed on 24 Oct 2025]

[45] Niederberger E,Geißlinger G.Pharmacological aspects of pain research in Germany.Schmerz2015;29:531-8. (in German)

[46] Te H.Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice.Clin Transplant2019;33:e13514

[47] Amacher DE.Drug-induced hepatic steatosis.Semin Liver Dis2014;34:205-14

[48] Kullak-Ublick GA,Merz M.Drug-induced liver injury: recent advances in diagnosis and risk assessment.Gut2017;66:1154-64 PMCID:PMC5532458